Business
Artelo Biosciences Provides Business Update and Reports First Quarter 2025 Financial Results
Several Key Clinical Readouts in Addition to New Study Initiations Expected in 2025SOLANA BEACH, Caif., May 13, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today provided a business update and announced its financial and operational results for the three months ended March 31, 2025. Busine
About this update from Artelo Biosciences, Inc.
[{"type":"image","alt":"Artelo Biosciences","displaySize":"","headline":null,"caption":"Artelo Biosciences","className":"","disableSlideshowImg":false,"size":{"original":{"width":183,"height":80,"url":"https://media.zenfs.com/en/globenewswire.com/0fcfe43e16f7cfc8e2a0ef70f1c6364e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/dtRWcM_YXYcz7bexobLzxA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTM2MDtoPTE1NztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/0fcfe43e16f7cfc8e2a0ef70f1c6364e","width":183,"height":80}},"lazy":false},{"type":"text","content":"Several Key Clinical Readouts in Addition to New Study Initiations Expected in 2025","length":88,"tagName":"p"},{"type":"text","content":"SOLANA BEACH, Caif., May 13, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today provided a business update and announced its financial and operational results for the three months ended March 31, 2025.","length":420,"tagName":"p"},{"type":"text","content":"Business Highlights:","length":20,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"ART26.12:","length":9,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"The first selective fatty acid binding protein 5 (FABP5) inhibitor to enter clinical trials completed enrollment of its Phase I safety study in healthy volunteers. Data readout remains on track for the second quarter of 2025.","length":225,"tagName":"p"}]},{"val":[{"type":"text","content":"Newly published peer-reviewed data revealed ART26.12’s potential in psoriasis, expanding its potential therapeutic applications beyond oncology and pain associated with cancer treatments.","length":187,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":412,"olType":false}]},{"val":[{"type":"text","content":"ART27.13: ","length":9,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Initial data from its Phase 2 CAReS study in cancer anorexia-cachexia syndrome, expected during the third quarter of 2025.","length":122,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":122,"olType":false}]},{"val":[{"type":"text","content":"ART12.11","length":8,"tagName":"p"},{"type":"list","items":[{...